Search
forLearn
5 / 801 resultslearn Actsyl®
learn lycopene
learn ceramide 2
learn Cetyl Alcohol
Research
5 / 46 results
research Tumor Mapping in 2 Large Multigenerational Families With CYLD Mutations
CYLD mutations cause a variety of skin tumors with symptoms starting around age 16, and treatments are currently limited.
research Premature aging and cancer development in transgenic mice lacking functional CYLD
Lack of functional CYLD in mice leads to early aging and cancer.
research 1329 CENPV is a novel CYLD-interacting molecule regulating ciliary acetylated tubulin
CENPV, a new partner of CYLD, helps regulate ciliary acetylated tubulin and is overexpressed in certain skin tumors.
research O02 Ubiquitomics of CYLD-deficient skin tumours reveals dysregulation of hair follicle keratinocyte processes
CYLD deficiency in skin tumors disrupts hair follicle cell processes and protein secretion.
research O19 CYLD cutaneous syndrome tumours demonstrate increased NF-κB signalling and diminished collagen organisation.
Skin tumors with CYLD cutaneous syndrome show more NF-κB activity and less organized collagen.
Community Join
5 / 1000+ resultscommunity Selling KY19382 powder a novel activator of Wnt/β-catenin signaling
The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.
community Selling KY19382 powder a novel activator of Wnt/β-catenin signaling Product
Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.
community Lyphar Biotech. China source for RU58841
The conversation discusses the safety and trustworthiness of ordering RU58841 from Lyphar Biotech in China, with a focus on pricing and reliability. The user is seeking advice on whether to proceed with the purchase or consider alternative sources.
community Kintors interim report from 9-2-24 for everyone whos interested
Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.
community September 2021 update from Dr. Kang-Yell Choi [Korean "cure"]
Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.